key: cord-0881836-sc1tdwc1
authors: Szerb, Jennifer; Abbass, Syed-Ali-Akbar; Banfield, Jillian; Uppal, Vishal
title: A survey assessing the need for spinal chloroprocaine to provide subarachnoid neuraxial anesthesia for short-duration surgeries in Canada
date: 2021-04-12
journal: Can J Anaesth
DOI: 10.1007/s12630-021-01980-w
sha: 1de686bb09c996afb5196072507137004d1db4c3
doc_id: 881836
cord_uid: sc1tdwc1

nan

Ontario Medical Association in active practice. To prevent inadvertent survey duplication by OA members responding to the CAS email, a prominent warning not to participate in the survey if it had been completed via other sources was included in their recruitment letter. The survey questions were developed using focused discussion (Appendix) and tested within the authorship team. The survey was conducted from 1 December 2020 to 4 January 2021 using the REDCap (Research Electronic Data Capture) platform. Descriptive statistics were performed on all variables, with categorical data reported as counts and percentages.

The CAS and OA survey response rates were 379/2218 (17%) and 81/1720 (5%) respectively, yielding a total of 460 consenting respondents. Twenty-seven were excluded (eight for not being in active practice and 19 for noncompletion), leaving 433 for analysis (see Electronic Supplementary Material [eAppendix] for detailed responses).

Two hundred and twenty-seven participants (52%) had experience using CP. Participants reported their primary work setting as an academic institute or university hospital (239), community hospital (224), or private clinic (12). Prior to the COVID-19 pandemic, 73% estimated the number of short surgical procedures amenable to SAB to be at least three or more per week.

During the pandemic, 57% reported providing SAB for short procedures sometimes, often, or always. If CP were available, 92% of respondents would provide SAB sometimes, often, or always. The choice of local Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12630-021-01980-w) contains supplementary material, which is available to authorized users. anesthetic (LA) for SAB for short procedures was as follows: bupivacaine 65%, lidocaine 18%, mepivacaine 16%, and other 2%. Free text answers for those that wrote ''other'' were ropivacaine, a mixture of LAs, opioid added to LA, or CP.

Participants were asked to choose the main barriers to SAB provision and click all that applied. Eighty-six percent of respondents chose prolonged time for SAB regression, causing delayed discharge readiness (Table) . The second most common barrier (72%) was the lack of a reliable short-acting LA without risk of transient neurologic symptoms. Lack of personnel, insufficient time, and lack of space were minor barriers.

Sixty-nine percent responded that access to spinal CP for SAB in short duration surgeries would be of ''considerable help'' or ''extremely helpful''. Previous experience using CP impacted the assessment of its usefulness such that 50% of those with experience felt CP would be ''extremely helpful'', compared with 14% with no experience using the drug. Even with no experience, 40% felt CP would be of ''considerable help''. Lastly, 88% (381) of respondents answered that they were more likely to provide SAB for short surgical procedures during the COVID-19 pandemic compared with their pre-pandemic practice.

The low survey response rate (5%) for OA members was likely because most members belonged to the CAS and had already received the recruitment emails. No email list of non-CAS members exists in Ontario. Although we asked anesthesiologists to complete the survey once, the risk of some duplicate responses cannot be completely ruled out.

Respondents worked in a broad range of settings. Access to CP was deemed to be extremely helpful by 69% of Canadian anesthesiologists, and 52% had prior experience using CP. Experience with the drug, versus no experience, positively influenced the overall assessment of the helpfulness of CP availability to the provision of SAB.

This study shows that, at least prior to the COVID-19 pandemic, there were sufficient short surgeries taking place to justify a freely accessible CP supply. Until recently, CP was available for individual patients in Canada only through Health Canada's Special Access Program. This was not a practicable daily option given that the indication for release was the exceedingly rare allergy to amide LAs, with the additional requirements to state why a general anesthetic was not an option and to order the drug well in advance. It is unclear if the approval of CP importation will meet the demand for SAB-amenable short duration surgeries shown in this survey, given the limited export supply from the United States.

Canadian anesthesiologists identified the lack of a suitable short-acting LA as the major barrier to performing SAB for short duration surgery. Access to CP would allow anesthesiologists to tailor the anesthetic to permit rapid discharge, with a low risk of transient neurologic symptoms, solving the two most frequently identified barriers in this survey. The study further shows that the choice of anesthesia for short-duration surgery is dependent on accessibility to CP.

In the COVID-19 pandemic, it is imperative to have CP available. Access to SAB should be promoted not only to provide patient care options, patient satisfaction, safety, and environmental benefit, but also to protect perioperative staff from aerosolized particles during airway manipulation for general anesthesia. Eighty-eight percent of respondents are more likely to consider SAB for the prime anesthetic at this time. Given that this is the case, Canadian anesthesiologists should have ready access to this option within the LA armamentarium.

Reviving older drugs to deal with anesthesia drug shortages

Comparison of 2-chloroprocaine, bupivacaine, and lidocaine for spinal anesthesia in patients undergoing knee arthroscopy in an outpatient setting: a double-blind randomized controlled trial

Does spinal chloroprocaine pharmacokinetic profile actually translate into a clinical advantage in terms of clinical outcomes when compared to low-dose spinal bupivacaine? A systematic review and meta-analysis

Neuraxial anaesthesia and peripheral nerve blocks during the COVID-19 pandemic: a literature review and practice recommendations

Practice recommendations on neuraxial anesthesia and peripheral blocks during the COVID-19 pandemic

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgements We wish to thank the Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University for providing grant support (CAD 1600.00) to fund this project.Disclosures None.Funding statement Department of Anesthesia, Pain Management and Peri-operative Medicine, Dalhousie University Internal Grant.Editorial responsibility This submission was handled by Dr.Stephan K.W. Schwarz, Editor-in-Chief, Canadian Journal of Anesthesia/Journal canadien d'anesthe´sie.

Surgeons' or postanesthesia nurses' preference for general anesthesia 105 24Lack of space such as block room to provide parallel processing 68 16Insufficient time to provide SAB because of rapid operating room turn-over 62 14Lack of personnel to assist in the performance of SAB 19 4 SAB = subarachnoid blockade; TNS = transient neurologic symptoms